Mayne Pharma enters an exclusive US license agreement with TherapeuticsMD for the latter’s women’s health portfolio. Whether the deal will boost their precarious finances is an open question.
Australia-based Mayne Pharma has signed a transaction agreement and a related exclusive license agreement with TherapeuticsMD.
Mayne will pay $140m up front to TherapeuticsMD’s for its branded women’s health portfolio containing three drugs: Annovera, Imvexxy, and...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
